EyePoint, Inc. - 8-K Filing

EyePoint reports Q3 2026 net loss of $95.6 million and announces strategic pivot to DME program following failed wet AMD Phase 3 trials. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 12:05 UTC

Tickers: $EYPT

Read the full article at SEC EDGAR

Part of the story EyePoint, Inc. - 8-K Filing (3 articles)

More Regulatory news

Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
NEXGEL, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
TEREX CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Victory Capital Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
Nano Dimension Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
M-tron Industries, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:56 UTC
M-tron Industries, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:55 UTC